RxDoctor Payments Data

Marija Petrovic, MD

Psychiatry · Alexandria, VANPI 1225138530

Payments from drug & device makers

$918in general payments, 2019–2025

Across 29 payments — averaging $31.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$258
  • Teva Pharmaceuticals USA, Inc.$223
  • Shockwave Medical, Inc$101
  • Neurocrine Biosciences, Inc.$75
  • Alkermes, Inc.$65
  • AbbVie$61
  • plus $135 from 5 others

What the payments were for

  • Food & beverage$69576%
  • Education$22324%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$918 in reported general payments places this provider in the 70th percentile of 884 psychiatry providers in Virginia.

See all psychiatry providers in Virginia

Medicare billing

Part B allowed, 2024
$31,559
Medicare patients
72
Services billed
323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate402$1,219,751
Abilify MaintenaAripiprazole67$179,501
IngrezzaValbenazine Tosylate13$111,355
AristadaAripiprazole Lauroxil15$47,901
Risperdal ConstaRisperidone Microspheres26$46,616
Clozapine775$30,778
RexultiBrexpiprazole15$29,074
VraylarCariprazine Hcl16$23,009
Lurasidone Hcl179$16,691
Paliperidone ErPaliperidone155$16,357
Divalproex Sodium ErDivalproex Sodium426$12,381
Aripiprazole208$11,549
Olanzapine484$10,911
Haloperidol Decanoate195$10,138
Haloperidol274$10,122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$43$1,266,367428 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$19$208,57582 claims
Neurocrine Biosciences, Inc.Ingrezza$75$111,35513 claims
Alkermes, Inc.Aristada$65$47,90115 claims
AbbVieVraylar$61$23,00916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 884 psychiatry providers in Virginia.

Other psychiatry in Alexandria

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →